Article
Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Aug 2026
Sfogliarini Chiara, Bernardinelli Camilla, Tran Lien Hong, Corsetto Paola Antonia, Rizzo Angela Maria, Cattani Franca, Cesta Maria Candida, Allegretti Marcello, Della Torre Sara, Locati Massimo, Vegeto Elisabetta
Abstract excerpt
Macrophages are key effectors of innate immune responses and infection control, relying on Toll-like receptors (TLRs) to sense pathogens and adopt immunometabolic anti-infective phenotypes. Raloxifene (RAL) and tamoxifen (TAM) are selective estrogen receptor modulators (SERMs) known to reprogram macrophage inflammatory responses via estrogen receptor-independent mechanisms, including NRF2 activation. Although...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
